NCT06890871

Radiotherapy with Immunotherapy and Anti-Angiogenic Therapy for Advanced HER2-Negative Breast Cancer: a Single-Arm Study

Radiotherapy Combined with Immunotherapy and Anti-angiogenic Therapy in Patients with Advanced HER2-negative Breast Cancer：a Single-arm, Exploratory Clinical Study

• Status: Enrolling By Invitation
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 25 (estimated)
• Sponsor: Zhongnan Hospital · Academic / Other
• Sex: Female
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The treatment options for advanced HER2-negative breast cancer are limited. The single or combined drug therapy has a short remission time. Moreover, after multiple lines of treatment, patients are often in an awkward situation of "no more drugs available". And through literature research, it has been found that there is a synergistic effect between immunotherapy and anti-angiogenic therapy, as well as between radiotherapy and immunotherapy. This study will provide new approaches for the treatment of advanced HER2-negative breast cancer in the second-line setting, and offer new evidence-based medical evidence for patients with advanced HER2-negative breast cancer in the era of immunotherapy.

Conditions

• Breast Cancer, Metastatic Breast Cancer

Interventions

Type	Name	Description
RADIATION	Intensity-modulated radiotherapy	Radiotherapy With Immunotherapy and Anti-Angiogenic Therapy
DRUG	Immunotherapy Therapy	Radiotherapy With Immunotherapy and Anti-Angiogenic Therapy

Timeline

• Start date: 2024-08-08
• Primary completion: 2025-12-31
• Completion: 2025-12-31
• First posted: 2025-03-24
• Last updated: 2025-03-24

Locations

1 site across 1 country: China